Xenikos raises EUR 3.6 million

Xenikos B.V. (Nijmegen, the Netherlands) raised EUR 3.6 million ($4.6 million) in a series A round from Sanquin Blood Supply Foundation; Participatiemaatschappij Oost Nederland; and Innovation & Investment Fund Gelderland. Xenikos also secured a EUR 1.9 million ($2.4 million) loan from the Dutch Ministry of Economy, Agriculture and Innovation.

Xenikos is developing T-Guard, which is ricin toxin attached to two mAbs that target CD3 and CD7, to treat T cell mediated diseases. The company is initially focusing on steroid-resistant acute Graft-versus-Host disease (GVDH) and is preparing to start a Dutch Phase Ib/IIa trial. ...